Business Description

Enzo Biochem, Inc. is engaged in research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information. The Company is conducting research and development activities in the development of therapeutic products based on the Company's technology platform of genetic modulation and immune modulation. The Company also operates a clinical reference laboratory that offers and provides diagnostic medical testing services to the health care community. The business activities of the Company are performed by its three wholly owned subsidiaries, Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc.

The research and development, manufacturing and marketing of biomedical research products and tools are done through Enzo Diagnostics and the research and development of therapeutic products are done through Enzo Therapeutics. The operation of a clinical reference laboratory is performed by Enzo Clinical Labs. During fiscal 2000, approximately 37% of the Company's operating revenues were derived from product sales and approximately 63% was derived from clinical reference laboratory services. During fiscal 1999 and 1998, respectively, approximately 37% and 31% of the Company's operating revenues were derived from product sales and approximately 63% and 69% were derived from clinical reference laboratory services.

Enzo has developed a portfolio of proprietary technologies with a variety of research, diagnostic and therapeutic applications. The Company has developed a broad technology base for the labeling, detection, amplification and formatting of nucleic acids for gene analysis. It has also developed proprietary technologies in the areas of genetic antisense (antisense RNA) and immune regulation that it is using as a platform for a portfolio of novel therapeutics. In addition, Enzo has developed a novel therapeutic approach based on immune regulation. The Company is applying its expertise in immune regulation to develop proprietary therapeutics for the treatment of a variety of diseases, including HIV-1 infection, chronic hepatitis caused by HBV and HCV infection, graft versus host disease and ulcerative colitis.

Research and Diagnostic Products
Enzo is a leading developer and marketer of novel research tools for gene analysis. The Company manufactures over 300 products that may be sold individually or combined in a kit to meet the specific needs of the researcher. The Company markets these products to biomedical and pharmaceutical firms worldwide. These products include pre-formatted in situ kits marketed under the PathoGene brand name; pre-formatted microplate kits; membrane kits marketed under the MaxSense brand name; non-radioactive nucleic acid probes marketed under the BioProbe brand name; and a line of labeling and signaling systems and reagents.

Therapeutic Development Programs
Enzo has a number of therapeutics in various stages of development that are based on its proprietary genetic antisense and immune regulation technologies. The Company is developing complementary HIV-1 therapeutics utilizing both its genetic antisense and immune regulation technologies. The Company's HGTV-43 genetic antisense product is designed to deliver the antisense genes to targeted blood cells of patients infected with HIV-1. The Company is also developing a complementary approach to treat HIV infection and the related autoimmune aspect of the disease.

The Company is developing complementary Hepatitis B (HBV) therapeutics utilizing both its genetic antisense and immune regulation technologies. Its EHT899 immune regulation product is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. Enzo is also applying its genetic antisense to treat chronic active hepatitis. It has developed antisense genes that interfere with the replication of HBV. The Company is currently developing a vector that will specifically deliver the genes to liver cells. This product is in pre-clinical development.

Enzo is applying its immune regulation technology to treat inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's Disease. The Company is also applying its immune regulation technology to treat graft versus host disease. In addition, the Company is applying its technologies to develop a therapeutic that regulates the level of cholesterol in the body and a therapeutic designed to treat the hepatitis C virus. These therapeutics are in pre-clinical stages of development.

Management Team

Board of Director